Drug Trial Radar · NCT04457596
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,056
Actual
Start
Mar 2, 2021
Primary completion
Jan 31, 2028
Study completion May 31, 2035
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); Seagen Inc.
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib is in a class of medications called kinase inhibitors. It blocks HER2, which may help keep cancer cells from growing and may kill them. Giving T-DM1 in combination with tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Conditions
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2 Positive Breast Carcinoma
- Invasive Breast Carcinoma
- Multifocal Breast Carcinoma
- Synchronous Bilateral Breast Carcinoma
- Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab EmtansineBiological
Given IV
Placebo AdministrationDrug
Given PO
TucatinibDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified invasive disease-free survival (iDFS)Time frame: From randomization to one of the following events: invasive local, regional or distant recurrence, invasive contralateral breast cancer or death from any cause, assessed up to 10 years
Locations
1,176 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Thomas Hospital
Fairhope, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Banner MD Anderson Cancer Center
Gilbert, Arizona
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Banner-University Medical Center Phoenix
Phoenix, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
UCSF Cancer Center - Berkeley
Berkeley, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Tower Cancer Research Foundation
Beverly Hills, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Mercy Cancer Center - Carmichael
Carmichael, California
Mercy San Juan Medical Center
Carmichael, California
Eden Hospital Medical Center
Castro Valley, California
Community Cancer Institute
Clovis, California
John Muir Medical Center-Concord
Concord, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
Sutter Davis Hospital
Davis, California
City of Hope Comprehensive Cancer Center
Duarte, California
Epic Care-Dublin
Dublin, California
Kaiser Permanente Dublin
Dublin, California
Mercy Cancer Center - Elk Grove
Elk Grove, California
Showing 40 of 1,176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.